NZ Lymphoma / Leukaemia Research Review Issue 33

In this issue:

Leukaemia selection

Ibrutinib as initial therapy for CLL
Acalabrutinib in relapsed CLL
Targeting BCL2 with venetoclax in relapsed CLL
Discontinuing dasatinib in CML in CMR for >1 year
Defining CR after allogeneic haematopoietic cell transplant for AML
FCR achieves long-term disease-free survival in IGHV-mutated CLL

Lymphoma selection

MYC-IG rearrangements are negative survival predictors in immunochemotherapy-treated DLBCL
R-HCVAD/MA in newly diagnosed mantle-cell lymphoma
Rituximab maintenance after single-agent induction in follicular lymphoma
Second cancer risk after Hodgkin’s lymphoma treatment

Please login below to download this issue (PDF)